IDEXX Announces Novel Diagnostic Test for Kidney Injury, Expanding the Veterinary Industry’s Most Comprehensive Renal Testing Portfolio

The IDEXX Cystatin B Test can help vets discover kidney injury prior to modifications in kidney function, promoting much better client results

WESTBROOK, Maine, June 15, 2023 /PRNewswire/ — IDEXX Laboratories, Inc. (NASDAQ: IDXX), a worldwide leader in animal health care development, today revealed the launch of the very first veterinary diagnostic test for finding kidney injury in cats and dogs. According to a recent IDEXX study, as lots of as one-third of kidney cases seen by vets relate to kidney injury, and a medical diagnosis can be challenging due to subtle or nonspecific indications.¹ The IDEXX Cystatin B Test will be consisted of in test panels examining kidney health, discovering brand-new medical insights for an approximated 2 million client gos to yearly. These tests will be performed at IDEXX Reference Laboratories beginning later on this year in the U.S. and Canada, with strategies to present the test in Europe in 2024.

The kidneys are essential to the general health of a client, controling high blood pressure, electrolyte balance, and red cell production, and eliminating toxic substances. IDEXX SDMA screening offers vets with unequaled insights into kidney function, and the IDEXX Cystatin B Test will improve their view into kidney health by finding injury and supplying extra clearness when a modification in kidney function might not appear. Together, the IDEXX Cystatin B and IDEXX SDMA^® tests provide a detailed view of the kidneys by discovering structural injury and impaired kidney function.

“With the addition of the IDEXX Cystatin B Test, we are delighted to provide the market’s very first biomarker for kidney injury,” said Jay Mazelsky, IDEXX President and Chief Executive Officer. “The IDEXX portfolio of tests and innovations makes it possible for vets to step in earlier, advance treatment, and now discover kidney injury, leading to much better results throughout the lives of their clients.”

The IDEXX broadened kidney screening portfolio now consists of:

Story continues

• IDEXX Cystatin B Test, finding kidney injury with or without modifications in kidney function, supplying important insights in cases such as early toxic substance direct exposure.

• IDEXX SDMA^® Test and creatinine, assisting to develop a standard for kidney function for tracking and early kidney illness detection.

• IDEXX FGF-23 Test, enabling more positive suggestions of targeted treatment for cats identified with persistent kidney illness (CKD) by keeping track of phosphorous overload.

• Urine screening, supplying a much deeper understanding of overall kidney health by analyzing the physical and chemical homes of urine.

For more details on the IDEXX Cystatin B Test and IDEXX kidney health options, please see IDEXX Cystatin B.

A joint declaration from 3 charter member of the American College of Veterinary Nephrology and Urology highlights the worth this unique biomarker keeps in the market and lines up with a recent statement from the International Renal Interest Society (IRIS):

“The introduction of diagnostic biomarkers capable to discover the existence of severe kidney injury along with active and continuous kidney injury in advance of or in the lack of modifications in traditional markers of kidney function anticipate an essential advance in the examination of severe and persistent kidney illness in dogs. The advancement and recognition of Cystatin-B as an active kidney injury biomarker in dogs that will be easily available to vets has the possible to improve the future diagnostic and healing instructions of kidney illness. As nephrologists, we anxiously await this brand-new period of early illness discovery and management.”

Dr, Gilad Segev, DVM, Dip. ECVIM-CA (Internal Medicine)
American College of Veterinary Nephrology and Urology, Founding Member
Associate Professor of Veterinary Medicine
Head, Small Animal Internal Medicine
Koret School of Veterinary Medicine
The Hebrew University of Jerusalem

Dr. Shelly Vaden, DVM, PhD, DACVIM (SAIM)
American College of Veterinary Nephrology and Urology, Founding Member
Professor Internal Medicine (Nephrology and Urology)
Medical Director, Extracorporeal Therapies
Chief of Staff, Small Animal
North Carolina State University, College of Veterinary Medicine

Larry D. Cowgill, DVM, PhD, Dipl. ACVIM (SAIM)
American College of Veterinary Nephrology and Urology, Founding Member
Professor, Department of Medicine & Epidemiology
2108 Tupper Hall
School of Veterinary Medicine
University of California-Davis

About IDEXX
IDEXX is a worldwide leader in animal health care development. Our diagnostic and software and services produce clearness in the complex, continuously progressing world of veterinary medication. We assistance longer, fuller lives for family pets by providing insights and options that help the veterinary neighborhood worldwide make positive choices—to advance healthcare, enhance effectiveness, and build growing practices. Our developments likewise help make sure the safety of milk and water throughout the world and keep the health and wellness of individuals and animals. IDEXX Laboratories, Inc. belongs to the S&P 500^® Index. Headquartered in Maine, IDEXX utilizes almost 11,000 individuals and uses options and items to consumers in more than 175 nations. For more details about IDEXX, see: idexx.com. For media questions, please contact us at [email protected].

Note Regarding Forward-Looking Statements
This press release includes or might consist of positive declarations within the significance of the Private Securities Litigation Reform Act of 1995. Forward-looking declarations can be determined by the usage of words such as “anticipates,” “may,” “expects,” “plans,” “would,” “will,” “strategies,” “thinks,” “price quotes,” “should,” “job,” and comparable words and expressions. These positive declarations are meant to supply our existing expectation or projections of future occasions; are based upon existing price quotes, forecasts, beliefs, and presumptions; and are not warranties of future efficiency. Actual occasions or outcomes might vary materially from those explained in the positive declarations. These declarations go through threats, unpredictabilities, presumptions, and other crucial elements. Readers are warned not to put excessive dependence on such positive declarations since real outcomes might differ materially from those revealed or indicated. The reports submitted by IDEXX pursuant to United States securities laws consist of conversations of a few of these threats and unpredictabilities. IDEXX presumes no commitment to, and specifically disclaims any commitment to, update or modify any positive declarations, whether as an outcome of brand-new details, future occasions, or otherwise. Readers are encouraged to examine IDEXX’s filings with the United States Securities and Exchange Commission (which are available from the SEC’s EDGAR database at sec.gov and through IDEXX’s website at idexx.com).

References

1. Data on file at IDEXX Laboratories, Inc. Westbrook, Maine U.S.A.: Data from IDEXX worldwide study carried out August 2021–September 2021.

View initial material to download multimedia: https://www.prnewswire.com/news-releases/idexx-announces-novel-diagnostic-test-for-kidney-injury-expanding-the-veterinary-industrys-most-comprehensive-renal-testing-portfolio-301851414.html

SOURCE Idexx Laboratories, Inc.